L17 @ #ACR23 New therapy on horizon for cutaneous LE (CLE)? ⭐️AFIMETORAN ➡️ TLR7/8 inhibitor ➡️1st-in-cl
Tweet Content
L17 @ #ACR23
New therapy on horizon for cutaneous LE (CLE)?
⭐️AFIMETORAN
➡️ TLR7/8 inhibitor
➡️1st-in-class orally bioavailable, potent
⭐️Phase Ib trial
➡️Criteria:
👉18-65 yo SLE vs biopsy proven CLE
👉CLE Dz Area & Severity Index (CLASI-A) at least 6
👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb
Show on Archive Page
On
Display in Search Results
On
PDQ
Off